Patents by Inventor Jay S. Schneider

Jay S. Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10874749
    Abstract: A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition is suitable for administration to a patient comprising injecting the AAV or other human compatible virus into the brain by intracranial stereotaxic injunction; wherein the AAV's encoding for the Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof enhance and/or normalize levels of GM1 in neurons, providing both therapeutic relief and disease modifying effects in specific areas of the brain relevant to particular neurodegenerative diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 29, 2020
    Assignee: Thomas Jefferson University
    Inventors: Jay S. Schneider, David W. Anderson
  • Publication number: 20180214573
    Abstract: A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition is suitable for administration to a patient comprising injecting the AAV or other human compatible virus into the brain by intracranial stereotaxic injunction; wherein the AAV's encoding for the Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof enhance and/or normalize levels of GM1 in neurons, providing both therapeutic relief and disease modifying effects in specific areas of the brain relevant to particular neurodegenerative diseases.
    Type: Application
    Filed: July 21, 2016
    Publication date: August 2, 2018
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: David W. Anderson, Jay S. Schneider
  • Patent number: 9394558
    Abstract: Methods for purification and extraction of GM1 ganglioside from cells derived from sheep afflicted with GM1 gangliosidosis or from cells derived from human patients with GM1 gangliosidosis as stable and renewable sources of GM1.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: July 19, 2016
    Assignee: LZ Therapeutics, Inc.
    Inventors: Jay S. Schneider, Gerri Henwood, Robert Florentine, Christopher Barber
  • Publication number: 20160082026
    Abstract: A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.
    Type: Application
    Filed: June 1, 2015
    Publication date: March 24, 2016
    Inventors: Jay S. Schneider, John J. Koleng, Robert Florentine, David W. Anderson
  • Publication number: 20140309179
    Abstract: A method of treating or preventing a retinopathy such as glaucoma in a human patient in need thereof comprising administering one or more gangliosides to the patient.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 16, 2014
    Applicant: LZ Therapeutics, Inc.
    Inventors: Jay S. Schneider, Gerri Henwood, Robert Florentine, David W. Anderson
  • Publication number: 20120220544
    Abstract: A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 30, 2012
    Inventors: Jay S. Schneider, John J. Koleng, Robert Florentine, David W. Anderson
  • Publication number: 20120220763
    Abstract: Methods for purification and extraction of GM1 ganglioside from cells derived from sheep afflicted with GM1 gangliosidosis or from cells derived from human patients with GM1 gangliosidosis as stable and renewable sources of GM1.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 30, 2012
    Inventors: Jay S. Schneider, Gerri Henwood, Robert Florentine, Christopher Barber
  • Publication number: 20120220543
    Abstract: A method of treating or preventing a retinopathy such as glaucoma in a human patient in need thereof comprising administering one or more gangliosides to the patient.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 30, 2012
    Inventors: Jay S. Schneider, Gerri Henwood, Robert Florentine, David W. Anderson
  • Patent number: 7414034
    Abstract: The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brain. Antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of glutamic acid decarboxylase (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the thalamic motor nuclei for the downregulation of GABA receptors.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: August 19, 2008
    Assignee: Thomas Jefferson University
    Inventor: Jay S. Schneider
  • Patent number: 7160913
    Abstract: The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: January 9, 2007
    Assignee: Thomas Jefferson University
    Inventor: Jay S. Schneider
  • Publication number: 20040087596
    Abstract: The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.
    Type: Application
    Filed: September 11, 2003
    Publication date: May 6, 2004
    Inventor: Jay S. Schneider
  • Patent number: 6551993
    Abstract: The present invention involves the use of partial glycine agonists directed at the glycine modulatory site of the NMDA receptor to treat cognitive dysfunction in mammals with Parkinson's disease or schizophrenia.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: April 22, 2003
    Assignee: Thomas Jefferson University
    Inventor: Jay S. Schneider
  • Publication number: 20030060436
    Abstract: The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brain. Antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of glutamic acid decarboxylase (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the thatlamic motor nuclei for the downregulation of GABA receptors.
    Type: Application
    Filed: November 5, 1999
    Publication date: March 27, 2003
    Applicant: CLIFFORD KENT WEBER ESQ.
    Inventor: JAY S. SCHNEIDER